Download Files:
DTP3
$160 – $950
Products Details
Product Description
– DTP3 TFA is a potent and selective GADD45β/MKK7 inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1].
Web ID
– HY-100538
Storage Temperature
– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Shipping
– Blue Ice
Applications
– Cancer-Kinase/protease
Molecular Formula
– C26H35N7O5
References
– [1]Tornatore L, et al. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019 Apr 19;6:369-379.|[2]Tornatore L, et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell. 2014 Oct 13;26(4):495-508.
CAS Number
– 1809784-29-9
Molecular Weight
– 525.60
Compound Purity
– 98.05
SMILES
– O=C(N[C@H](CC1=CC=CC=C1)C(N)=O)[C@H](NC([C@H](NC(C)=O)CC2=CC=C(O)C=C2)=O)CCCNC(N)=N
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL
Target
– DNA/RNA Synthesis;JAK
Pathway
– Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Peptides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
